NCT01884584View on ClinicalTrials.gov

Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Malignant Neoplasm
Interventions
DRUG

Indocyanine green (ICG)

Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.

Trial Locations (3)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT01884584 - Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer | Biotech Hunter | Biotech Hunter